Sudarshan Pharma Industries Ltd (SUDARSHAN) is currently trading at 39.47 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sudarshan Pharma Industries Limited is a vertically integrated pharmaceutical and specialty chemicals company operating across R&D, intermediates, APIs, finished formulations and branded generics, with contract manufacturing, trading subsidiaries and an export-focused footprint spanning Asia, the Middle East, Africa and select Western markets. Financial momentum is notable: FY25 revenue reached INR 505.0 crore with EBITDA rising 75% to INR 39.9 crore and PAT improving to INR 16.0 crore, reflecting margin expansion driven by increased manufacturing sales, export ramp-up and mix improvement in resale of APIs and intermediates. Strategic expansion is evident through acquisitions (Ratna Lifesciences, Ishwari Healthcare), new subsidiaries in Singapore and Dubai, development of local Vitamin B1/B6 manufacturing, and a proposed USD 35 million FCCB — all indicating Sudarshan Pharma Industries Limited is mobilizing capital and assets to scale exports and reduce China dependency. Working capital intensity rose materially in FY25 with inventories at ~INR 140 crore, trade receivables ~INR 160 crore and short-term borrowings increasing to ~INR 160 crore, which alongside a higher debt-to-equity of 1.4x highlights Sudarshan Pharma Industries Limited's leverage and the need for disciplined cash conversion management. Market credibility is supported by a blue‑chip client list including Cipla, Dr. Reddy's, Biocon and others, and by regulatory-ready documentation (IP/BP/USP standards), positioning Sudarshan Pharma Industries Limited as a China+1 supply alternative for specialty chemicals, intermediates and selected APIs.

Over the past 52 weeks, Sudarshan Pharma Industries Ltd has traded between a low of ₹18.50 and a high of ₹42.79. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sudarshan Pharma Industries Ltd has a market capitalization of approximately 1,001.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sudarshan Pharma Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 40.02 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,001.38 Cr, Sudarshan Pharma Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sudarshan Pharma Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sudarshan Pharma Industries Ltd is 40.02. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.